Skip to main content
Equibles

RDHL · RedHill Biopharma Ltd.

Track RDHL — free

Use RDHL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research RDHL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.49 -0.01 (-1.44%) At close · Oct 5
Rebalance outlook locked
Market Cap
$3.04M
Shares
6.08M
Volume · Oct 5 91.87K Avg daily vol (3M) 1.79M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.49 Open$0.50 Day$0.49–0.51 52W close$0.48–1.99 Avg vol 30d3.8M Short int235K · 3.9% float · 1.0d Short vol25% Last earningsMar 31, 2022 DataJan 2020–Oct 2026

Up next

Q1 2022 earnings call transcript
call held Mar 31, 2022

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-77.5%
Trailing year
Short interest
3.9%
Latest settlement · 1.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 15.5 · calm Equity put/call 0.59
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −44%
below
Price vs 50-day avg −20%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −32%
trailing
6-month return −39%
trailing
YTD return −52%
this year
Relative strength −51%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-13% holders QoQ · +2 funds added
Insider flow Distributing
Net -$1.4K over 90 days · 100% sells
Short interest Rising
3.87% of float · ▲ +2710.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Squeeze score 43
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 89%
annualized · 1-yr
Max drawdown −76%
past year
ATR 10.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−44% Bearish
Price vs 50-day avg
−20% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
-13% holders QoQ · +2 funds added
Insider flow Distributing
Net -$1.4K over 90 days · 100% sells
Short interest Rising
3.87% of float · ▲ +2710.1% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 1% Range high $2
vs 200-day avg -44% vs 50-day avg -20%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RDHL
RedHill Biopharma Ltd.
this stock
$3.04M -52.2% — — 3.9%
TAK
Takeda Pharmaceutical Co Ltd
 $60.23B +14.2% — — 0.1%
GALDY
Galderma Group AG/ADR
 $46.00B -6.1% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $45.67B +27.1% +4.3% 64.3 2.7%
HLN
Haleon plc
 $40.72B -12.8% — — 0.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
14
% held
5.2%
Net QoQ
-202.8K sh
Top holder
Yorkville Advisors Global…
Held Float
View
Held by Funds
Fund positions
1
View
Short & Settlement
Short Interest Rising
Shares short
235.3K
Days to cover
1.0d
Change
+226.9K sh
View
Short Volume
Short vol %
25%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
284
Value
$182
As of
Sep 14, 2026
View
Off-Exchange
Off-exchange %
52.3%
Week of
Aug 31, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.4K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 30, 2026
This year
28
View
Exempt Offerings
Offering
$10.0M
Filed
Feb 5, 2024
View
Earnings & Events
Webcasts
Last webcast
Mar 31, 2022
View
Investor Relations
Latest news
RedHill Biopharma Announces Opera…
Published
Sep 30, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
RDHL -2.5% -32.0% -39.2% +2.7% -52.2%
SPY +1.2% +0.6% +11.6% +1.6% +13.6%
vs SPY -3.7% -32.6% -50.7% +1.1% -65.8%
Key facts CIK 1553846 CUSIP 757468301 Visit website Investor relations